

## Cellnovo Joins the Diabeloop© Artificial Pancreas Development Programme

### Release of a New Version of the Insulin Pump Software

**Paris, France, June 17, 2015** – Cellnovo Group (“Cellnovo”), a medical technology company that has developed and markets the first connected all-in-one diabetes management system, announced today that it had joined the Diabeloop© Artificial Pancreas Programme and had released a new version of its insulin pump software.

Cellnovo is announcing that it is joining the Diabeloop© Artificial Pancreas program by supplying its unique patch pump and mobile diabetes management technologies. Diabeloop© is a research association between the CERIDT, a general interest leading diabetes research institution and service provider in France and the CEA-LETI, the French government’s main research and development institution. Ten leading French university hospitals are participating in this project. The Cellnovo R&D team will be joining the Diabeloop© research consortium by further developing its pump and handset software to allow the development of an artificial pancreas system. The overall Diabeloop© project is currently the subject of a special financing application with the French government in the form of an FUI (Fonds Unique Interministériel).

Development and CE marking programmes will span three years, the first clinical trials starting at the end of 2015.

The Company also released on May 13<sup>th</sup> a new version of its pump software preventing the reuse of discarded insulin cartridges as had been reported in two instances in the UK. Shipments were resumed in the UK and France, prioritizing existing patients.

*“We are extremely pleased to see that our insulin pump and our mobile diabetes management system have been recognized by the Diabeloop© SAS, subsidiary of the CERITD, as key technologies for this leading artificial pancreas project. We look forward to having our R&D teams in the UK and France participate in this research.”* said Eric Beard, Chairman of Cellnovo.

Dr. Guillaume Charpentier, president of the CERITD, said: *“We welcome Cellnovo as a preferred partner in our Artificial Pancreas research program with their unique patch pump technology and mobile health approach. We look forward to cooperating with Cellnovo on this exciting research and integrating their system in our forthcoming clinical trials. The feedback from patients using the Cellnovo system in France has been extremely positive and the CERITD has now begun to offer this system to its patients in the Centre Hospitalier Sud Francilien”.*



## The First Connected All-in-one Diabetes Management System

### About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. With Cellnovo's device, certain aspects of diabetes management still require an action from the patient (blood glucose monitoring and injection of insulin just before meals). This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real-time.

Cellnovo aims to improve the quality of life of patients with type 1 diabetes and, more generally, all people living with insulin dependency by using its technology to minimise the constraints and risks associated with this illness.

The current version of the system has already received CE Marking, is reimbursed in most countries and is already being marketed in France and the United Kingdom. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product's commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to cope with the expected high level of demand.

The insulin pump market is currently estimated to be worth around 2.2 billion dollars, and has substantial potential given that only 17% of the 3.5 million people with type 1 diabetes (in the US/Canada and main European countries) currently use a pump. Based in France and the United Kingdom, Cellnovo has a 75-strong workforce.

For further information please visit [www.cellnovo.com](http://www.cellnovo.com)

#### Cellnovo

Sophie Baratte  
[investors@cellnovo.com](mailto:investors@cellnovo.com)

#### NewCap

Relations investisseurs  
Antoine Denry  
[cellnovo@newcap.fr](mailto:cellnovo@newcap.fr)  
+ 33 1 44 71 94 95

#### NewCap

Relations Médias  
Nicolas Merigeau  
[cellnovo@newcap.fr](mailto:cellnovo@newcap.fr)  
+33 1 44 71 98 55

### About CERITD:

CERITD is a non-profit organization ("loi 1901") created to ease the burden of diabetes for patients by offering them care and tools tailored to their everyday life. CERITD offers care to patients outside of the hospital through specialized nurses. It has a unique contract as delegate for public care. CERITD currently has 3 centers and aims to spread to 10 centers by 2016.

Within its research projects, CERITD initiated the Diabeloop project along with 10 university hospitals and the CEA Leti. Leveraging the CERITD experience of creating automated care tools, Diabeloop includes close monitoring and follow-up of specialized nurses, assuring a permanent link with the diabetes specialists following the patients.

#### CERITD

Dr. Jean-Hugues Masgnaux  
Directeur  
[Jeanhugues.masgnaux@ceritd.fr](mailto:Jeanhugues.masgnaux@ceritd.fr)  
+33 1 64 96 91 98

#### Diabeloop SAS

Mr. Erik Huneker  
CEO  
[info@diabeloop.fr](mailto:info@diabeloop.fr)  
+33 6 52 66 37 80

### About the Artificial Pancreas and Diabeloop®:

An artificial pancreas device system is a system of devices that closely mimics the glucose regulating function of a healthy pancreas. Key devices in an artificial Pancreas are a Continuous Glucose Monitor (CGM) and an insulin infusion pump both connected by computer-controlled algorithms, with safety assured by remote alert algorithms. The Artificial Pancreas will greatly improve treatment for type 1 diabetes patients. It will decrease hypoglycemia events, reduce the serious complications associated with diabetes (blindness, cardiovascular, amputations) and dramatically increase quality-of-life for the diabetes patients. One of the key characteristics of CERITD's artificial pancreas is to be associated with human care through connected nurses and doctors.